NCT07919028
A Clinical Trial of MK-7602 in Healthy Volunteers (MK-7602-006)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Area Under the Curve From Time 0 to the Next Dosing Interval (AUC0-tau) of MK-7602
Timeframe: At designated timepoints (up to approximately 21 days)
Maximum Plasma Concentration (Cmax) of MK-7602
Timeframe: At designated timepoints (up to approximately 21 days)
Number of Participants Who Experience an Adverse Event (AE)
Timeframe: Up to approximately 2 months
Number of Participants Who Discontinue Study Intervention Due to an AE
Timeframe: Up to approximately 20 days
Secondary (2)
AUC0-tau of MK-7602
Cmax of MK-7602
Arms and interventions
Period 1: MK-7602Experimental
Participants will receive an oral dose of MK-7602 once daily on Days 1, 2, and 3 of Period 1.
Period 2: MK-7602 + PyronaridineExperimental
Participants will receive oral doses of MK-7602 and pyronaridine once daily on Days 1, 2, and 3 of Period 2.
Drugs: MK-7602, Pyronaridine